DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) announced today an agreement with Bristol-Myers Squibb Company (BMS) under which it will perform a phosphoproteomic research project employing its PhosphoScan® technology to provide BMS with cellular phospho-profiles of a small-molecule kinase inhibitor.
